Targeting Homologous Recombination Repair in Cancer - DNA Repair in Cancer Therapy - page 156

expression: a phase III trial in non-small-cell lung cancer. J Clin
Oncol 2007;25(19):2747 e 54.
373. Lyakhovich A, Surralles J. Disruption of the Fanconi anemia/
BRCA pathway in sporadic cancer. Cancer Lett 2006;232(1):
99 e 106.
374. Lisby M, Barlow JH, Burgess RC, Rothstein R. Choreography of
the DNA damage response: spatiotemporal relationships among
checkpoint and repair proteins. Cell 2004;118(6):699 e 713.
375. Bekker-Jensen S, Mailand N. Assembly and function of DNA
double-strand break repair foci in mammalian cells. DNA Repair
2010;9(12):1219 e 28.
376. Yuan SS, Lee SY, Chen G, Song M, Tomlinson GE, Lee EY. BRCA2
is required for ionizing radiation-induced assembly of Rad51
complex in vivo. Cancer Res 1999;59(15):3547 e 51.
377. Tarsounas M, Davies D, West SC. BRCA2-dependent and inde-
pendent formation of RAD51 nuclear foci. Oncogene 2003;22(8):
1115 e 23.
378. Dray E, Etchin J, Wiese C, et al. Enhancement of RAD51 recom-
binase activity by the tumor suppressor PALB2. Nat Struct Mol
Biol 17(10): 1255-9.
379. Tan TL, Essers J, Citterio E, et al. Mouse Rad54 affects DNA
conformation and DNA-damage-induced Rad51 foci formation.
Curr Biol 1999;9(6):325 e 8.
380. Wiese C, Dray E, Groesser T, et al. Promotion of homologous
recombination and genomic stability by RAD51AP1 via RAD51
recombinase enhancement. Mol Cell 2007;28(3):482 e 90.
381. Feng Z, Scott SP, Bussen W, et al. Rad52 inactivation is syntheti-
cally lethal with BRCA2 deficiency. Proc Natl Acad Sci USA 2011;
108(2):686 e 91.
382. Tebbs RS, Hinz JM, Yamada NA, et al. New insights into the
Fanconi anemia pathway from an isogenic FancG hamster CHO
mutant. DNA Repair (Amst) 2005;4(1):11 e 22.
383. Scully R, Chen J, Plug A, et al. Association of BRCA1 with Rad51
in mitotic and meiotic cells. Cell 1997;88(2):265 e 75.
384. Scully R, Chen J, Ochs RL, et al. Dynamic changes of BRCA1
subnuclear location and phosphorylation state are initiated by
DNA damage. Cell 1997;90(3):425 e 35.
385. Kennedy RD, D'Andrea AD. DNA repair pathways in clinical
practice: lessons from pediatric cancer susceptibility syndromes.
J Clin Oncol 2006;24(23):3799 e 808.
386. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA
double-stranded breaks induce histone H2AX phosphorylation
on serine 139. J Biol Chem 1998;273(10):5858 e 68.
387. Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M,
Bonner WM. A critical role for histone H2AX in recruitment of
repair factors to nuclear foci after DNA damage. Curr Biol 2000;
10(15):886 e 95.
388. Redon CE, Nakamura AJ, Zhang YW, et al. Histone gammaH2AX
and poly(ADP-ribose) as clinical pharmacodynamic biomarkers.
Clin Cancer Res 2010;16(18):4532 e 42.
389. Kinner A, Wu W, Staudt C, Iliakis G. Gamma-H2AX in recogni-
tion and signaling of DNA double-strand breaks in the context of
chromatin. Nucleic Acids Res 2008;36(17):5678 e 94.
390. Ismail IH, Hendzel MJ. The gamma-H2A.X: is it just a surrogate
marker of double-strand breaks or much more? Environ Mol
Mutagen 2008;49(1):73 e 82.
391. Taneja N, Davis M, Choy JS, et al. Histone H2AX phosphoryla-
tion as a predictor of radiosensitivity and target for radiotherapy.
J Biol Chem 2004;279(3):2273 e 80.
392. Crul M, van Waardenburg RC, Bocxe S, et al. DNA repair
mechanisms involved in gemcitabine cytotoxicity and in the

interaction between gemcitabine and cisplatin. Biochem Pharmacol
2003;65(2):275 e 82.
393. Strumberg D, Pilon AA, Smith M, Hickey R, Malkas L,
Pommier Y. Conversion of topoisomerase I cleavage complexes
on the leading strand of ribosomal DNA into 5'-phosphorylated
DNA double-strand breaks by replication runoff. Mol Cell Biol
2000;20(11):3977 e 87.
394. Olive PL, Banath JP. Kinetics of H2AX phosphorylation after
exposure to cisplatin. Cytometry B Clin Cytom 2009;76(2):79 e 90.
395. Asakawa H, Koizumi H, Koike A, et al. Prediction of breast
cancer sensitivity to neoadjuvant chemotherapy based on status
of DNA damage repair proteins. Breast Cancer Res 2010;12(2). R17.
396. Willers H, Taghian AG, Luo C-M, Treszezamsky AD, Sgroi D,
Powell SN. Utility of DNA repair protein foci for the detection of
putative BRCA1-pathway defects in breast cancer biopsies. Mol
Cancer Res 2009;7:1304 e 9.
397. Kachnic LA, Fournier L, Gheorghiu L, Rosenberg C, Powell SN,
Willers H. Utility of chemotherapy-induced Rad51 foci for the
identification of homologous recombination defects in breast
cancer cell lines. Proceedings of the 55th Annual Meeting of the
Radiatation Research Society, Savannah, GA 2009:99.
398. Vaira V, Fedele G, Pyne S, et al. Preclinical model of organotypic
culture for pharmacodynamic profiling of human tumors. Proc
Natl Acad Sci USA 107(18): 8352-6.
399. Behbod F, Kittrell FS, LaMarca H, et al. An intraductal human-in-
mouse transplantation model mimics the subtypes of ductal
carcinoma in situ. Breast Cancer Res 2009;11(5). R66.
400. Mukhopadhyay A, Elattar A, Cerbinskaite A, et al. Development
of a functional assay for homologous recombination status in
primary cultures of epithelial ovarian tumor and correlation with
sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin
Cancer Res 16(8): 2344-51.
401. Olive PL, Banuelos CA, Durand RE, Kim JY, Aquino-Parsons C.
Endogenous and radiation-induced expression of gammaH2AX
in biopsies from patients treated for carcinoma of the uterine
cervix. Radiother Oncol 2010;94(1):82 e 9.
402. Banuelos CA, Banath JP, Kim JY, Aquino-Parsons C, Olive PL.
gammaH2AX expression in tumors exposed to cisplatin and
fractionated irradiation. Clin Cancer Res 2009;15(10):3344 e 53.
403. Sedelnikova OA, Bonner WM. GammaH2AX in cancer cells:
a potential biomarker for cancer diagnostics, prediction and
recurrence. Cell Cycle 2006;5(24):2909 e 13.
404. Solier S, Pommier Y. The apoptotic ring: a novel entity with
phosphorylated histones H2AX and H2B and activated DNA
damage response kinases. Cell Cycle 2009;8(12):1853 e 9.
405. Wang LH, Pfister TD, Parchment RE, et al. Monitoring drug-
induced gammaH2AX as a pharmacodynamic biomarker in
individual circulating tumor cells. Clin Cancer Res 2010;16(3):
1073 e 84.
406. Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy
caused by intragenic deletion in BRCA2. Nature 2008;451(7182):
1111 e 5.
407. Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as
a mechanism of cisplatin resistance in BRCA2-mutated cancers.
Nature 2008;451(7182):1116 e 20.
408. Janne PA. Challenges of detecting EGFR T790M in gefitinib/
erlotinib-resistant tumours. Lung Cancer 2008;60(Suppl. 2):S3 e 9.
409. Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T.
Secondary BRCA1 mutations in BRCA1-mutated ovarian carci-
nomas with platinum resistance. Cancer Res 2008;68(8):2581 e 6.